Objective Impaired lysosomal degradation of αsynuclein and other cellular constituents
may play an important role in Parkinson's disease (PD). Rare genetic variants in the …

Background: Genetic, biologic and clinical data suggest that Parkinson's disease (PD) is an
umbrella for multiple disorders with clinical and pathological overlap, yet with different …

Variants in multiple lysosomal enzymes increase Parkinson's disease (PD) risk, including
the genes encoding glucocerebrosidase (GCase), acid sphingomyelinase (ASMase) and …

Parkinson's disease (PD) is one of the progressive neurological diseases which affect
around 10 million population worldwide. The clinical manifestation of motor symptoms in PD …

Parkinson's disease (PD) is the second most common neurodegenerative disorder in the
aging population, and no disease-modifying therapy has been approved to date. The …

Point mutations in the αsynuclein coding gene may lead to the development of Parkinson's
disease (PD). PD is often accompanied by other psychiatric conditions, such as anxiety …

It is well established that lysosomal glucocerebrosidase gene (GBA) variants are a risk factor
for Parkinson's disease (PD), with increasing evidence suggesting a loss of function …

Sphingolipid metabolism starts with the biosynthesis of ceramide, a bioactive lipid and the
backbone for the biosynthesis of complex sphingolipids such as sphingomyelin and …

Aim We have previously reported that cambinol (DDL-112), a known inhibitor of neutral
sphingomyelinase-2 (nSMase2), suppressed extracellular vesicle (EV)/exosome production …

The association between glucocerebrosidase, encoded by GBA, and Parkinson's disease
(PD) highlights the role of the lysosome in PD pathogenesis. Genome-wide association …